ArticleCancer cell international2021
Engineered exosomes loaded with miR-449a selectively inhibit the growth of homologous non-small cell lung cancer.
Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Optimizing miRNA Loading into Platelet Exosomes via Electroporation: A Comparative Analysis of Buffer Systems and Voltage Parameters for Enhanced Targeted Drug Delivery.Molecular biotechnology · 2026Article
- Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer.Cancer gene therapy · 2026Review
- Transforming Cancer Care with Oncosomes: Insight into Biogenesis, Functional Role, and Therapeutic Potential.Pharmaceutics · 2026Review
- Therapeutic Potential of Bovine Colostrum- and Milk-Derived Exosomes in Cancer Prevention and Treatment: Mechanisms, Evidence, and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Recent advances in engineered exosome-based therapies for ocular vascular disease.Journal of nanobiotechnology · 2025Review
- Exosomes in inflammation and cancer: from bench to bedside applications.Molecular biomedicine · 2025Review
- Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials.Molecular pharmaceutics · 2025Review
- Inhalable Exosomes in Respiratory Therapies with the Transformative Potential.International journal of nanomedicine · 2025Review
- Exosomal microRNAs: impact on cancer detection, treatment, and monitoring.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Exosome therapeutics for non-small cell lung cancer tumorigenesis.Cancer cell international · 2024Review
- [Research Progress of Engineered Exosomes in the Treatment of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Suppression of gastric cancer cell proliferation by miR-494-3p inhibitor-loaded engineered exosomes.Heliyon · 2024Article
- Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives.Cancers · 2024Review
- MicroRNA Nano-Shuttles: Engineering Extracellular Vesicles as a Cutting-Edge Biotechnology Platform for Clinical Use in Therapeutics.Biological procedures online · 2024Review
- Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma.Neuro-oncology · 2024Article
- Unraveling the Connection: Extracellular Vesicles and Non-Small Cell Lung Cancer.International journal of nanomedicine · 2024Review
- Investigating the role of exosomal microRNA-5703 in modulating tumor-associated endothelial cells in lung cancer.CytoJournal · 2024Article
- Strategies for Targeting Peptide-Modified Exosomes and Their Applications in the Lungs.International journal of nanomedicine · 2024Review
- A review on the current literature regarding the value of exosome miRNAs in various diseases.Annals of medicine · 2023Review
- Engineered extracellular vesicles-like biomimetic nanoparticles as an emerging platform for targeted cancer therapy.Journal of nanobiotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an efficient drug carrier, exosome has been widely used in the delivery of genetic drugs, chemotherapeutic drugs, and anti-inflammatory drugs. As a genetic drug carrier, exosomes are beneficial to improve transfection efficiency and weaken side effects at the same time. Here, we use genetic engineering to prepare engineered exosomes (miR-449a Exo) that can actively deliver miR-449a. It was verified that miR-449a Exo had good homology targeting capacity and was specifically taken up by A549 cells. Moreover, miR-449a Exo had high delivery efficiency of miR-449a in vitro and in vivo. We demonstrated that miR-449a Exo effectively inhibited the proliferation of A549 cells and promoted their apoptosis. In addition, miR-449a Exo was found to control the progression of mouse tumors and prolong their survival in vivo. Our research provides new ideas for exosomes to efficiently and actively load gene drugs, and finds promising methods for the treatment of non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.